Powered by: Motilal Oswal
8/03/2021 2:12:33 PM | Source: Accord Fintech
Sun Pharma gains as its arm to acquire stake in WRS Bioproducts Pty
News By Tags | #642 #572 #999
Sun Pharma gains as its arm to acquire stake in WRS Bioproducts Pty

Sun Pharmaceutical Industries is currently trading at Rs. 618.55, up by 7.60 points or 1.24% from its previous closing of Rs. 610.95 on the BSE.

The scrip opened at Rs. 613.20 and has touched a high and low of Rs. 621.70 and Rs. 612.20 respectively. So far 69287 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 653.70 on 12-Feb-2021 and a 52 week low of Rs. 315.20 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 636.45 and Rs. 597.45 respectively. The current market cap of the company is Rs. 148302.89 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 33.03% and 12.49% respectively.

Sun Pharmaceutical Industries’ one of the wholly owned subsidiaries has agreed to acquire by way of allotment to it, 428,571 ordinary shares (equivalent to 12.5% fully diluted equity stake) of WRS Bioproducts Pty, Australia. WRS Bioproducts Pty develops novel technologies to produce and commercialize supplements and nutraceutical ingredients from diverse algae species in Australia.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here